Provided by Tiger Trade Technology Pte. Ltd.

DELCATH SYSTEMS INC

10.37
-0.0200-0.19%
Post-market: 10.700.3349+3.23%18:05 EST
Volume:772.40K
Turnover:8.09M
Market Cap:366.20M
PE:300.53
High:10.65
Open:10.61
Low:10.30
Close:10.39
52wk High:18.23
52wk Low:8.12
Shares:35.31M
Float Shares:34.03M
Volume Ratio:1.30
T/O Rate:2.27%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.0345
EPS(LYR):-0.9255
ROE:1.94%
ROA:4.71%
PB:3.19
PE(LYR):-11.21

Loading ...

Company Profile

Company Name:
DELCATH SYSTEMS INC
Exchange:
NASDAQ
Establishment Date:
1987
Employees:
96
Office Location:
566 Queensbury Avenue,New York,New York,United States
Zip Code:
12804
Fax:
212 489 2102
Introduction:
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.

Directors

Name
Position
John Sylvester
Non-Executive Chairman
Gerard Michel
CEO and Director
Elizabeth Czerepak
Director
Gilad Aharon
Director
Roger G. Stoll
Director
Steven Salamon
Director

Shareholders

Name
Position
John Purpura
Chief Operating Officer
Johnny John
Senior Vice President Clinical Development and Medical Affairs
Gerard Michel
CEO and Director